首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1820532

全球囊性纖維化治療市場研究報告 - 產業分析、規模、佔有率、成長、趨勢及預測（2025 年至 2033 年）

Global Cystic Fibrosis Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年09月01日 | 出版商:

Value Market Research | 英文 129 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球囊性纖維化治療市場預測將大幅成長，預計到 2033 年市場規模將飆升至 743.1 億美元，較 2024 年的 194.3 億美元大幅成長。這一擴張反映了 2025 年至 2033 年期間預計的 16.07% 的驚人年複合成長率(CAGR)。

隨著精準醫療和基因編輯技術的出現，囊性纖維化治療市場正在快速發展。針對CFTR蛋白的新型調節因子正在徹底改變治療模式，提供更佳的療效和個人化的治療方案。生物標記驅動的診斷與即時患者監測的結合正在改善臨床療效，並促成自適應治療策略。未來的發展預計將側重於聯合療法和針對潛在基因突變的下一代基因療法，預計將囊性纖維化從慢性疾病轉變為可控制或可治癒的疾病。

基於RNA的療法和CRISPR-Cas9基因編輯的新興研究有望帶來持久干預，在分子層面上糾正基因缺陷。病患登記和資料分析平台的擴展正在加速藥物開發和上市後監測。此外，包括可吸入製劑和奈米載體在內的藥物傳輸系統的進步正在提高生物利用度和患者依從性。隨著治療格局的演變，市場將見證生物技術創新者和醫療保健提供者之間日益加強的合作，從而推動創新並擴大尖端治療的可及性。

我們的報告經過精心設計，旨在為客戶提供關於各個行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵部分，以確保客戶全面了解市場格局：

市場概況：對市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本部分探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準，將市場細分為不同的細分市場。此分析重點在於突出每個細分市場的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本部分深入分析了領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，對特定時期的市場規模和成長趨勢進行預測。這包括定量分析和圖形表示，以說明未來的市場發展軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前及新興市場趨勢、技術創新和潛在投資領域。本部分提供對未來市場發展和成長前景的洞察。

涵蓋的細分市場列表

囊性纖維化治療市場報告的這一部分提供了國家和地區層面的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

CFTR調節劑
胰酵素補充劑
黏液溶解劑
支氣管擴張劑

依給藥途徑

口服
吸入

按配銷通路

醫院藥房
零售藥局
網路藥局
報告中介紹的公司列表
AbbVie Inc.、F. Hoffmann-La Roche Ltd、Gilead、Novartis AG、Vertex Pharmaceuticals Incorporated、AIT（先進吸入療法）、Alaxia、Teva Pharmaceutical Industries Ltd.、Merck & Co. Inc.、Sionna Therapeutics、Alcresta Therapeutics Inc.、AstraZeneca.

如果您有任何客製化需求，請聯絡我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美各細分市場銷售分析
- 北美各國銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲各細分市場銷售分析
- 歐洲各國銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區分部銷售分析
- 亞太地區國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲各細分市場銷售分析
- 拉丁美洲各國銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲分部銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東和非洲其他地區銷售分析

第9章：囊性纖維化治療公司的競爭格局

囊性纖維化治療市場競爭
夥伴關係/合作/協議
併購
新產品發布
其他發展

第10章：公司簡介

頂級公司市佔率分析
市場集中度
AbbVie Inc.

公司概況
公司收入
產品
最新動態

F. Hoffmann-La Roche Ltd

公司概況
公司收入
產品
最新動態

Gilead

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

Vertex Pharmaceuticals Incorporated

公司概況
公司收入
產品
最新動態

AIT (Advanced Inhalation Therapies)

公司概況
公司收入
產品
最新動態

Alaxia

公司概況
公司收入
產品
最新動態

Teva Pharmaceutical Industries Ltd.

公司概況
公司收入
產品
最新動態

Merck & Co. Inc.

公司概況
公司收入
產品
最新動態

Sionna Therapeutics

公司概況
公司收入
產品
最新動態

Alcresta Therapeutics Inc.

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，或者在私人公司的情況下可能不涵蓋

簡介目錄圖表

Product Code: VMR112116811

The forecast for the Global Cystic Fibrosis Therapeutics market predicts substantial growth, with market size projected to soar to USD 74.31 Billion by 2033, a significant increase from the USD 19.43 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 16.07% anticipated between 2025 and 2033.

The cystic fibrosis therapeutics market is advancing rapidly with the advent of precision medicine and gene-editing technologies. Novel modulators targeting the CFTR protein are revolutionizing treatment paradigms, offering improved efficacy and personalized therapeutic regimens. The integration of biomarker-driven diagnostics and real-time patient monitoring is enhancing clinical outcomes and enabling adaptive treatment strategies. Future developments are expected to focus on combination therapies and next-generation gene therapies that address the underlying genetic mutations, potentially transforming cystic fibrosis from a chronic condition to a manageable or curable disease.

Emerging research in RNA-based therapeutics and CRISPR-Cas9 gene editing holds promise for durable interventions that correct genetic defects at the molecular level. The expansion of patient registries and data analytics platforms is facilitating accelerated drug development and post-market surveillance. Additionally, advancements in drug delivery systems, including inhalable formulations and nanocarriers, are improving bioavailability and patient compliance. As the therapeutic landscape evolves, the market will witness increased collaboration between biotech innovators and healthcare providers, driving innovation and expanding access to cutting-edge treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Cystic Fibrosis Therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

CFTR Modulators
Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators

By Route of Administration

Oral
Inhaled

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
List of Companies Profiled in the report
AbbVie Inc., F. Hoffmann-La Roche Ltd, Gilead, Novartis AG, Vertex Pharmaceuticals Incorporated, AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Sionna Therapeutics, Alcresta Therapeutics Inc., AstraZeneca

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CYSTIC FIBROSIS THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data Analysis By Drug Class
5.3. CFTR Modulators Historic and Forecast Sales By Regions
5.4. Pancreatic Enzyme Supplements Historic and Forecast Sales By Regions
5.5. Mucolytics Historic and Forecast Sales By Regions
5.6. Bronchodilators Historic and Forecast Sales By Regions

6. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Oral Historic and Forecast Sales By Regions
6.4. Inhaled Historic and Forecast Sales By Regions

7. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
7.4. Retail Pharmacies Historic and Forecast Sales By Regions
7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CYSTIC FIBROSIS THERAPEUTICS COMPANIES

9.1. Cystic Fibrosis Therapeutics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF CYSTIC FIBROSIS THERAPEUTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. AbbVie Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. F. Hoffmann-La Roche Ltd
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Gilead
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Novartis AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Vertex Pharmaceuticals Incorporated
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. AIT (Advanced Inhalation Therapies)
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Alaxia
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Teva Pharmaceutical Industries Ltd.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Merck & Co. Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Sionna Therapeutics
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Alcresta Therapeutics Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. AstraZeneca
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments